Dr. Lobbous is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center
9500 Euclid Avenue/CA51
Cleveland, OH 44195Phone+1 216-445-1379Fax+1 216-444-0924
Education & Training
- University of Alabama at Birmingham School of Public HealthMSPH, Epidemiology , 2018 - 2021
- University of Alabama Medical CenterResidency, Neurology, 2014 - 2018
- Ain Shams University Faculty of MedicineClass of 2012
Certifications & Licensure
- KY State Medical License 2024 - 2025
- MN State Medical License 2024 - 2025
- OH State Medical License 2021 - 2025
- AL State Medical License 2016 - 2022
- American Board of Psychiatry and Neurology Neurology
- United Council for Neurology SubspecialtiesNeuro-Oncology
Publications & Presentations
PubMed
- 5 citationsRacial and socioeconomic disparities in glioblastoma outcomes: A single-center, retrospective cohort study.Dagoberto Estevez-Ordonez, Moaaz Abdelrashid, Elizabeth Coffee, Nicholas M B Laskay, Travis J Atchley
Cancer. 2023-10-01 - 6 citationsCauda equina syndrome in an ovarian malignant-mixed müllerian tumor with leptomeningeal spread.Joshua D. Bernstock, Stuart A. Ostby, Brandon M. Fox, Houman Sotoudeh, Andrew Janssen
Clinical Case Reports. 2019-10-22 - 49 citationsAn Update on Neurofibromatosis Type 1-Associated GliomasMina Lobbous, Joshua D. Bernstock, Elizabeth Coffee, Gregory K. Friedman, Laura K. Metrock
Cancers. 2020-01-01
Journal Articles
- An evaluation of selumetinib for the treatment of neurofibromatosis type 1-associated symptomatic, inoperable plexiform neurofibromasKatie Metrock, Mina Lobbous, Bruce Korf, Expert Review of Precision Medicine and Drug Development, 7/2021
Books/Book Chapters
Abstracts/Posters
- Phase 1 trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified γδ t cells and temozolomide chemotherapy in newly diagnosed glioblastomaLouis B. Nabors, Lawrence S. Lamb, Melissa Jo Beelen, Thriumaine Pillay, Mariska ter Haak, Samantha Youngblood, Louis Vaickus, Mina Lobbous, ASCO 2021
- Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and cape...Erica Michelle Stringer-Reasor, Barbara Jane O'Brien, Ariel Topletz-Erickson, Jason B White, Mina Lobbous, Kristen Riley, Jennifer Childress, Kim LaMaster, Michelle E...., ASCO 2021
- Phase 2 trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001Katherine B. Peters, John L. Villano, Nicholas A. Butowski, Adam Louis Cohen, Joe Sammy Mendez, Pierre Giglio, Chi Zhang, Shahzad Raza, Tresa McGranahan, Mina Lobbous,..., ASCO 2021
Other
- Prevalence of asymptomatic glioma and implications for survivalWarren PP, Lobbous M, Peeri NC, Thompson ZJ, Thompson RC, Olson JJ, LaRocca RV, Chowdhary SA, Anderson MD, Vogelbaum MA, Markert JM, Nabors LB, Egan KM
https://www.medrxiv.org/content/10.1101/2020.04.27.20080564v1
MedRxiv - 2020
Press Mentions
- IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual MeetingNovember 11th, 2023
- UAB Reports Promising Phase 1 Glioblastoma Treatment Data at ASCOJune 6th, 2024
- I’m a Top Neurologist. This Is a Common Sign of Brain Cancer That People Often IgnoreJune 21st, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: